tiprankstipranks
Alterity announces DMC recommends to continue Phase 2 study of ATH434-201
PremiumThe FlyAlterity announces DMC recommends to continue Phase 2 study of ATH434-201
2M ago
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
PremiumPress Releases
Alterity Therapeutics Phase 2 Data Monitoring Committee Recommends Continuing Clinical Trial as Planned After Third Review
2M ago
Alterity Therapeutics Gains Momentum in Q3
PremiumCompany Announcements
Alterity Therapeutics Gains Momentum in Q3
2M ago
Alterity Therapeutics’ ATH434 Shows Treatment Promise
PremiumCompany AnnouncementsAlterity Therapeutics’ ATH434 Shows Treatment Promise
2M ago
Alterity Therapeutics Adds New Shares Post-Options
PremiumCompany Announcements
Alterity Therapeutics Adds New Shares Post-Options
2M ago
Alterity announces presentations of data on Parkinson’s Disease, MSA
PremiumThe Fly
Alterity announces presentations of data on Parkinson’s Disease, MSA
3M ago
Alterity Therapeutics Shareholders Approve Resolutions
PremiumCompany AnnouncementsAlterity Therapeutics Shareholders Approve Resolutions
3M ago
Alterity Therapeutics’ Resolutions Pass Unanimously
PremiumCompany Announcements
Alterity Therapeutics’ Resolutions Pass Unanimously
3M ago
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
PremiumPress Releases
Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024
3M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100